Welcome to our dedicated page for Upstream Bio SEC filings (Ticker: UPB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Upstream Bio, Inc. (NASDAQ: UPB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as it advances verekitug, a monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor, through clinical development. As a clinical-stage biotechnology company, Upstream Bio uses SEC reports to communicate trial progress, financial results, and other material information relevant to shareholders.
Recent Form 8-K filings referenced by the company include announcements of quarterly financial results and business highlights, as well as the furnishing of press releases and presentations. For example, an 8-K dated August 6, 2025, furnished a press release summarizing second quarter financial results and updates on Phase 2 trials in CRSwNP, severe asthma, and COPD. Another 8-K dated November 5, 2025, furnished third quarter results and program progress, while an 8-K dated September 2, 2025, furnished the press release and presentation describing positive top-line data from the VIBRANT Phase 2 CRSwNP trial.
Through these filings, investors can see how Upstream Bio reports collaboration revenue, research and development expenses related to verekitug, general and administrative expenses, and net loss figures, as well as balance sheet items such as cash, cash equivalents, and short-term investments. The filings also describe the design and endpoints of key clinical trials when they are the subject of a furnished press release.
On Stock Titan, these documents are supplemented with AI-powered summaries that highlight the main points of each filing, helping readers quickly understand what changed in a given quarter or event filing. Users can review 8-Ks tied to clinical data releases, financial updates, and other corporate communications, and use this information alongside news and price data when evaluating UPB.
Upstream Bio, Inc. (UPB) outlined pivotal Phase 3 development plans for its lead drug candidate verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The company will run one placebo-controlled Phase 3 trial in each indication using a single high-dose 400 mg subcutaneous regimen administered every 12 weeks, enrolling approximately 1,500 patients in total.
Primary endpoints include annualized asthma exacerbation rates over 48 weeks for asthma and co-primary nasal polyp and congestion scores at 48 weeks for CRSwNP. Upstream Bio plans to initiate both Phase 3 trials in the first quarter of 2027 and, with supportive results, expects to submit BLAs to the FDA for both indications, targeting potential U.S. launch of verekitug as early as 2030. Verekitug has already been studied in more than 500 participants with positive Phase 2 results in severe asthma and CRSwNP and is also being evaluated in an ongoing Phase 2 COPD trial.
Norges Bank, the central bank of Norway and an investment adviser, reports its beneficial ownership of common stock of Upstream Bio, Inc. on an amended Schedule 13G. Norges Bank reports beneficial ownership of 4,206,586 shares of common stock, representing 7.7299% of the class.
Of this position, Norges Bank has 3,768,619 shares with sole power to vote and 3,768,619 shares with sole power to dispose. It reports 437,967 shares with shared power to dispose and no shared voting power. Certain shares are reported as invested on behalf of the Government of Norway, and Norges Bank certifies that its foreign regulatory scheme is substantially comparable to that of functionally equivalent U.S. institutions.
Upstream Bio, Inc. is a clinical-stage biotech focused on verekitug, a monoclonal antibody targeting the TSLP receptor for severe asthma, CRSwNP, and COPD. The company reported a net loss of $39.7 million for the quarter and $80.3 million for the six months ended June 30, 2026, compared with $67.2 million a year earlier.
Collaboration revenue from its Maruho agreement was modest at $1.8 million for the first half. Research and development expenses rose to $72.7 million, driven mainly by advancing Phase 2 programs and Phase 3 planning, while general and administrative expenses were $15.1 million. Cash, cash equivalents and short-term investments totaled $261.3 million, and the company states this should fund operations through 2027. Upstream also has a $150 million at-the-market equity program, of which about $2.1 million has been used so far.
Upstream Bio, Inc. reported second quarter 2026 results and provided an update on development of its lead asset, verekitug, for severe inflammatory respiratory diseases. As of June 30, 2026, cash, cash equivalents and short‑term investments totaled $261.3 million, which the company expects will fund planned operations through 2027.
For the quarter ended June 30, 2026, collaboration revenue was $0.8 million. Research and development expenses were $36.1 million and general and administrative expenses were $7.1 million, leading to a net loss of $39.7 million, similar to the $40.0 million net loss a year earlier.
Operationally, Upstream highlighted progress toward planned Phase 3 trials of verekitug in severe asthma and CRSwNP targeted for the first quarter of 2027, completion of enrollment in the Phase 2 VENTURE COPD trial with 481 participants, and additional supportive Phase 2 data presentations in CRSwNP and severe asthma.
BlackRock, Inc. reported a passive ownership stake in BIO INC common stock on Schedule 13G. BlackRock beneficially owns 2,814,714 shares, representing 5.2% of the outstanding common stock, with sole voting power over 2,764,429 shares and sole dispositive power over 2,814,714 shares.
The filing notes that various underlying clients or investors have rights to receive dividends or sale proceeds from these shares, but no single such person has an interest in more than five percent of BIO INC’s total outstanding common shares.
Upstream Bio, Inc. reported that CFO and COO Michael Gray sold 853 shares of common stock at $6.10 per share. After this transaction, he directly holds 28,795 shares. According to the disclosure, the sale was automatic under a sell-to-cover policy to satisfy tax withholding on vested restricted stock units.
Upstream Bio, Inc. Chief Executive Officer Everett Rand Sutherland reported an open-market sale of 2,095 shares of common stock at $6.10 per share. According to the filing, these shares were sold automatically under the company’s sell-to-cover policy to satisfy tax withholding obligations tied to vesting restricted stock units, not at the CEO’s discretion. Following this tax-related sale, he directly holds 70,812 shares of Upstream Bio common stock.
Upstream Bio, Inc. Chief Business Officer Adam Houghton reported an automatic sale of common stock tied to tax withholding on vested restricted stock units. He sold 700 shares at $6.10 per share under the company’s sell-to-cover policy, which executes sales without his discretion. After this transaction, he directly holds 23,601 shares of Upstream Bio common stock, so the filing reflects tax-related administration rather than a discretionary change in his investment position.
Upstream Bio, Inc. reported that Chief Medical Officer Aaron Deykin sold 895 shares of common stock at $6.10 per share on June 16, 2026. According to the company’s sell-to-cover policy, these shares were sold automatically to cover tax withholding on vested restricted stock units and were not sold at his discretion.
After this transaction, Deykin directly holds 33,197 shares of Upstream Bio common stock, which includes 1,405 shares previously acquired under the company’s 2024 Employee Stock Purchase Plan.
Upstream Bio, Inc. General Counsel Allison Ambrose reported an automatic sale of common stock tied to tax withholding on vested restricted stock units. On this transaction date, 477 shares were sold at $6.10 per share under a company "sell-to-cover" policy, and Ambrose held 16,048 shares of common stock afterward.